

1 **Prenatal carrier screening for spinal muscular atrophy among Thai pregnant women**

2

3 Chayada Tangshewinsirikul¹, Panyu Panburana¹, Maneerat Prakobpanich², Takol

4 Chareonsirisuthigul³, Donniphat Dejsuphong⁴, Thipwimol Tim-aroon⁵, Chaiyos

5 Khongkhatithum⁶, Thanyachai Sura⁷, Atchara Tunteeratum⁷, Duangrurdee Wattanasirichaigoon^{5*}

6 ¹ Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Faculty of

7 Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

8 ² Department of Obstetrics and Gynecology, Faculty of Medicine Ramathibodi Hospital, Mahidol

9 University, Bangkok, Thailand

10 ³ Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University,

11 Bangkok, Thailand

12 ⁴ Section for Translational Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol

13 University, Bangkok, Thailand

14 ⁵ Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine Ramathibodi

15 Hospital, Mahidol University, Bangkok, Thailand

16 ⁶ Division of Neurology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital,

17 Mahidol University, Bangkok, Thailand

18 ⁷ Division of Medical Genetics, Department of Internal Medicine, Faculty of Medicine

19 Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

20 *Corresponding author

21 E-mail: duangrurdee.wat@mahidol.ac.th

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36 **ABSTRACT**

37 **Objectives.** To investigate the acceptance rate for spinal muscular atrophy (SMA) carrier
38 screening among Thai pregnant women, their attitudes toward the prenatal screening, carrier rate,
39 and the frequencies of *SMN2* copy numbers.

40 **Materials and methods.** Singleton pregnant women who aged ≥ 18 years, with a gestational age
41 of ≤ 14 weeks at their first visit, were invited to participate the study. All participants completed
42 the questionnaire: Section I - demographic data. Then, they received a pre-test group counseling,
43 followed by an offer of SMA carrier testing at no cost and completion of the questionnaire:
44 Section II - awareness and attitudes toward the screening and Section III – reasons for their
45 choosing ‘to have’ or ‘not to have’ the screening done. Only those having the test done and
46 undergoing post-test counseling were asked to complete the questionnaire: Section IV – attitudes
47 toward the screening process.

48 **Results.** We found a high acceptance rate for carrier screening at 91.4% (181/198 participants), a
49 carrier rate of 2.2% (1 in 45), and high frequency of ≤ 2 copies of *SMN2* (98.3%). The preexisting
50 knowledge about SMA was low (30.8%). The majority of participants became realized about the
51 severity of SMA and its burden to the families (94.4%) and agreed to have fetal diagnosis if they
52 were found to be a couple-at-risk (92.4%). Most participants (98%) suggested that SMA carrier
53 screening should be offered to all pregnant women and that the cost of testing should be covered
54 by the government and/or by their health coverage schemes (95.5%).

55 **Conclusion.** The high acceptance rate and positive attitude toward prenatal SMA carrier was
56 demonstrated among Thai pregnant women. Data from the present study highlight urgent needs

57 for endorsement from professional society and public health policy in advancing the SMA carrier
58 screening program in Thailand.

59 **Key words:** spinal muscular atrophy, SMA, prenatal, carrier screening, attitude

60

61

62

63

64

65

66

67

68

69

70

71

72

73 Introduction

74 Spinal muscular atrophy (SMA) is a severe neuromuscular disorder which results in
75 progressive muscle weakness, with an estimated incidence of 1 in 6,000-10,000 births worldwide
76 [1]. SMA is divided into four clinical types depending on the age of onset and clinical
77 progression. Type I SMA (Werdnig–Hoffmann) has clinical onset within the first three months
78 of life, usually leading to respiratory failure and death by two years of age. The onset of type II
79 SMA is 6-18 months of age, and the affected children may sit independently but cannot stand or
80 walk, with 70% surviving beyond 25 years of age. Patients with type III SMA (Kugelberg–
81 Welander), with the onset at ≥ 18 months, have difficulty climbing stairs and running and often
82 have a normal lifespan. Type IV SMA or adult-onset SMA is described with slow progression of
83 muscle weakness beginning at around 30 years of age, and with no reduction in life expectancy
84 [2]. Type I SMA has the highest incidence among SMA, at 50-60% [2-5]. However, there is a
85 marked difference between incidence and prevalence of type I SMA because of its low survival
86 [6-7]. Among the living individuals with SMA, types II and III together account for 75-83% [6-
87 9].

88 Survival motor neuron 1 (*SMN1*) gene, located on 5q11.2–q13.3, is the disease-causing
89 gene of SMA. Approximately 95-98% of SMA cases are caused by a homozygous deletion of
90 exon 7 or exons 7-8 of the *SMN1* gene, with 3%–5% being due to point mutation or compound
91 heterozygosity between the deletion and point mutations [2]. *SMN2* is a highly homologous gene
92 of *SMN1*, they are located next to each other. The complete absence of *SMN2* yields no clinical
93 effect on healthy individuals. The copy number of *SMN2* rather modifies the severity of SMA [2,
94 6, 10]. Most people have two copies of *SMN1*, each on the homologous chromosome, and two
95 copies of *SMN2*, each on the homologous chromosome as well [2,11], The higher number of

96 *SMN2* copy number is associated with less severity of the SMA phenotypes (1 copy of *SMN2*:
97 96% - type I SMA; 2 copies: 79% - type I; 3 copies: 54% - type II and 31% - type III/IV; ≥ 4
98 copies: 88% - type III/IV) [2]. Therefore, simultaneous copy number detection of *SMN1*-exon 7
99 (or exons 7-8) and *SMN2*-exon7 is widely used for molecular diagnosis and prognostication for
100 SMA [2,12]. As for carrier screening in general population, copy number analysis of the *SMN1* is
101 a preferred method, owing to its high throughput, rapid turn-around time, and economical reason
102 [13-15].

103 Carrier frequency of SMA in general population is high at approximately 1 in 33-94
104 worldwide [2, 11, 13, 15, 16], and potentially with the most severe phenotype due to the high
105 frequency of ≤ 2 copies of *SMN2* among the carriers [15, 17-21]. Screening for SMA carrier
106 before conception or early in pregnancy, regardless of religion or ethnicity, has been
107 recommended by the American College of Medical Genetics (2008) and by the American
108 College of Obstetricians and Gynecology (2017) [22, 23].

109 Thailand is a middle-income country with well-established universal health coverage
110 (UHC) since 2002 (<https://eng.nhso.go.th/>) Almost all Thai citizens are currently covered by one
111 of the three health benefit schemes: 74% under the Thai UHC, 7% covered by the Civil Servant
112 Medical Benefit Scheme (CSMBS, for government/state employees), and 19% under the Social
113 Security Scheme (SSS for working adults). Notably, 93% of Thai Children are covered by the
114 UHC. Prenatal screening for thalassemia (carrier rate 40%) has been offered as the national
115 policy since 1992, with a good coverage at 98% of pregnant women [24, 25]. Carrier frequency
116 of SMA among Thai population is 1 in 40 [26, 27], but SMA carrier screening is not included in
117 the national program or routine antenatal care in the country. Newborn screening for SMA is not
118 offered and specific treatments for SMA (such as mRNA-modifying treatment and gene therapy)

119 is not reimbursable under the existing health schemes in the country. Carrier testing for SMA and
120 reproductive choices are offered to only the families with previous affected child/relatives with
121 SMA.

122 To explore the potentials for establishing carrier screening for SMA during prenatal
123 period, we set off to conduct this study. Our objectives were to assess the acceptance rate of the
124 carrier screening among Thai pregnant women, to evaluate their attitudes toward the screening,
125 to determine the prevalence of SMA carrier and the frequencies of *SMN2* copy numbers.

126 **Materials and Methods**

127 ***Study design and participants***

128 This was a prospective and descriptive study, conducted during 10 March 2021 and 31
129 March 2022, at the antenatal care clinic, Ramathibodi Hospital. The protocol was granted by the
130 Ramathibodi Hospital Institutional Review Board (COA, MURA2020/1420) and complied with
131 the Declaration of Helsinki. The study was registered as a clinical trial (registration number
132 NCT04859179).

133 Eligible participants were women with singleton pregnancy, who were aged ≥ 18 years
134 and capable of reading and understanding Thai, and with a gestational age of ≤ 14 weeks at their
135 first visit with our antenatal care clinic. They were invited to enroll in the study, by one of the
136 authors (MP) and asked to provide a written informed consent. Exclusion criteria were refusal to
137 give a written consent, withdrawal during or after the completion of the study, and insufficient
138 data obtained from the questionnaire.

139 ***Questionnaire***

140 A Thai-language questionnaire was developed using information from a literature review,
141 then validated by six clinical experts: two maternal and fetal medicine specialists, two pediatric
142 geneticists, and two clinical scientists. The reliability of the questionnaire was 0.797, as assessed
143 by using Cronbach's alpha.

144 The questionnaire contained four sections, I-IV. Section I focused on the participants'
145 demographic data, including age, education, occupation, religion, and gravida and previous
146 history of fetal anomalies. Section II asked about awareness and attitudes toward SMA carrier
147 screening. This section comprised of nine question items, including the awareness of severity of
148 SMA and its burden on the patients and families, the usefulness and interest in having prenatal
149 carrier screening for SMA and their confidence in the reliability of the test offered, agreement in
150 having definitive test for fetal diagnosis, possible considering termination of pregnancy as an
151 alternative if the fetus to be found affected, opinion on having SMA carrier screening as part of a
152 standard antenatal care, and their willingness to self-pay for the screening test. The answer
153 options were 'agree', 'not sure', and 'disagree'.

154 As for Section III, we explored the reason(s) and/or rationale thinking of the participants
155 for choosing 'to have' or 'not to have' the carrier screening test. Multiple choice answers were
156 provided to choose and the participants could choose more than one answer as wanted. We also
157 asked the participants' opinions on a reasonable price for the screening test if it had to be self-
158 pay, and who (individuals, organizations, health schemes, or else), in their opinion, should be
159 responsible for cost of testing if the screening would become part of standard antenatal care in
160 the country.

161 Section IV consisting five question items, was about the participants' attitudes and
162 reflections of their immediate past experience with going through the SMA carrier screening

163 process including pre-test and post-test counselling: overall feeling/satisfaction to the screening
164 process, the usefulness of the information provided, the essence of post-test counseling, the
165 whole process is time worthy, and that the carrier screening should be offered to all pregnant
166 women during antenatal visit. The answer options for each question were ‘agree’, ‘not sure’, and
167 ‘disagree’.

168 ***Data collection***

169 All the participants, after the completion of Section I of the questionnaire, were provided
170 with pre-test group counseling delivered by trained maternal and fetal medicine specialists using
171 a PowerPoint presentation which lasted for about 10 minutes. The participants then received the
172 Thai-language brochure to read in a designated area, this was to allow the participants time to
173 digest the information received and self-check of their understanding. The slide presentation for
174 the group counseling and the brochure contained similar information, including the incidence,
175 clinical presentations, natural course and outcomes of SMA; treatment options and the efficacy
176 of available treatments, affordability of the treatment in the country; carrier rate and carrier
177 screening; and prenatal diagnosis and its downstream services.

178 After pre-test counseling, a free-of-charge SMA carrier testing (as part of this research)
179 was offered to all participants and they were asked to complete the questionnaire Sections II and
180 III, regardless of their choosing to have the test done or not. A sequential prenatal SMA carrier
181 screening protocol was established to use in this research (Figure 1). For those choosing not to
182 have the test done, the study ended at this point. About those choosing to have carrier testing
183 performed, 10-ml of venous blood sample was taken for *SMN1* and *SMN2* analysis.

184 Post-test counseling for each individual was offered by a maternal and fetal medicine
185 specialist at an antenatal care clinic, upon the result became available. Then, the participants
186 were requested to finalize the Section IV of the questionnaire. For those who were found to be a
187 carrier, their partner was counseled and offered the carrier testing (with no charge). Prenatal
188 diagnosis would be discussed to a couple at risk.

189 *Carrier testing and copy numbers analysis for SMN1 and SMN2*

190 To detect copy number of *SMN1* and *SMN2*, we performed multiple ligation-dependent
191 probe amplification (MLPA) analysis, using a commercially available MLPA kit for SMA
192 (SALSA P021), following the manufacturer's protocol (MRC Holland, Amsterdam, the
193 Netherlands). The MLPA reactions included internal quality controls and negative controls. The
194 PCR products were analyzed using the Applied Biosystems 3500 Genetic Analyzer
195 (ThermoFisher Scientific, MA, USA) and Coffalyser.net software (MRC Holland), following the
196 manufacturer's instructions. The tests were performed at the Human Genetics Laboratory,
197 Ramathibodi Hospital. Carrier status, in the present study, is defined as having only 1 copy of
198 *SMN1* exon 7. The results of carrier testing were reported to the clinician researchers (CT, PP,
199 and MP) within two weeks.

200 *Statistical analyses*

201 Categorical variables were described as the number (percent). Parametric continuous
202 variables were expressed as a mean and standard deviation.

203 **Results**

204 A total of 237 pregnant women were assessed, 35 did not meet the inclusion criteria and
205 four declined to participate, leaving 198 (83.5%) of eligible participants to be enrolled in the

206 study. Among 181 out of 198 (91.4%) research participants who took the screening test, four
207 were identified as carriers of SMA. Their partners were screened, and none was found to be a
208 carrier, resulting in no couple at risk detected in the present study (Figure 2).

209 The mean age of the participants was 32 ± 5.1 years and over half (66.2%) of them had a
210 Bachelor's degree or higher (Table 1). None had a child or family relative(s) with SMA. Two-
211 thirds of the participants said that they had never heard of SMA before.

212 *Acceptance and attitudes toward SMA carrier screening*

213 Around 95% or over of the participants agreed that SMA is a serious disorder resulting in
214 severe life suffering, and that the carrier screening could reduce unnecessary anxiety during
215 pregnancy and it should be offered to all pregnant women (Table 2). About 80-92% or more of
216 the participants expressed that having a child with SMA would complicate their life, they were
217 not reluctant to have the screening test done, they had a good faith in the accuracy of the test, and
218 they would have fetal diagnosis if they would be found to be a couple at risk (Table 2). Almost
219 half of the participants expressed their tendency to choose termination of pregnancy for an
220 affected fetus (Table 2).

221 In the present study, the most common reasons for having the carrier screening included
222 wanting to know their carrier status (87.8%), being worried to have an affected fetus (72.9%),
223 and no extra cost for the test (50.3%) (Table 3). As for those declining the test, they reasoned
224 that SMA was rarely found (58.8%) (Table 3).

225 Almost half of the participants (47.7%) said that they could afford 501–1,000 Baht (~14-
226 28 USD) if self-pay for the SMA carrier screening. Most participants (95.5%) thought that the

227 cost of carrier testing should be covered by the government and/or their health coverage schemes
228 (Table 4).

229 After receiving the result of screening test, all the participants expressed the feeling of
230 glad that they had had the test done. They all agreed that the information about SMA provided to
231 them were very useful and that post-test counseling was essential (Table 5).

232 *SMA carrier rate and frequencies of SMN2 copy number*

233 Only 2.2% (4/181) of the participants were found to be carrier (Table 6). As for the
234 *SMN2*, the majority of participants had 2 copies (58.5%), followed by ≤ 1 copy (39.8%), and ≥ 3
235 copies (1.7%). Regarding the carrier individuals, three had 2 copies and the other had 1 copy of
236 *SMN2*.

237 **Discussion**

238 We found a high acceptance rate for prenatal SMA carrier testing (91.4%) and positive
239 attitudes towards the screening test, among the pregnant women in this study. Most participants
240 (92%) would choose fetal diagnosis if they were found to be a couple at risk and consider having
241 interruption of pregnancy in case of affected fetus (47%), these finding were in agreement with
242 earlier studies [13, 15]. The majority of the participants suggested SMA carrier testing to be part
243 of standard antenatal care and covered by the public health system.

244 The low awareness of SMA among the participants, were probably due to the rarity of the
245 disorder; being a hidden problem of SMA owing to the short life of significant proportion of the
246 patients, the patients' low social activities because of respiratory and ambulatory difficulties; and
247 the lack of public health education and screening services for SMA [9, 28, 29].

248 Despite of generally low awareness of SMA prior to the study, the acceptance rate for
249 SMA prenatal carrier screening was high among the participants in the present study, likely due
250 to several factors including the knowledge about SMA given, perceived usefulness of the pre-
251 and post-test counseling provided, trust in the test offered, testing at no extra cost (Table 3), and
252 availability of the downstream services. Some studies have shown a significantly increased
253 acceptance rate if covered by medical insurance/health scheme (97.8%) compared to self-funded
254 screening (81.1%) [29, 30]. Other influencing factors included race, parity, and religion [17, 29].

255 As for those declining the screening test, the main reasons were the low prevalence of
256 SMA (58.8%) and not choosing interruption of the pregnancy for an affected fetus (17.6%). Our
257 findings were consistent with previous reports that people without SMA experience had
258 significantly lower rate of taking carrier testing because they had a dimmer view of the condition
259 than those with experiential knowledge [29, 31]. Therefore, the endorsement from public health
260 authority and professional society and effective mass communications are urgently needed in
261 advancing the SMA carrier screening program [29-31].

262 The SMA carrier rate found in this study was 1 in 45, with estimated prevalence of SMA
263 at 1 in 8,264, similar to those found worldwide [11, 13, 15, 16, 17-21, 26, 27]. The majority
264 (98.3%) of the participants had ≤ 2 copies of *SMN2*, suggesting that a major proportion of Thai
265 affected individuals (fetuses) would be predicted to have the most severe phenotype (type I) of
266 SMA, consistent with other studies [2, 11].

267 To establish a new prenatal carrier screening program in any country, it is essential to
268 have testing that is acceptable to the target population, with timely turnaround time, appropriate
269 pre-test and post-test counseling, and affordable downstream services including testing for the
270 partners, fetal diagnosis, and choices of continuation and interruption of pregnancy. Other local

271 context, such as affordable treatment and predicted severity of the disorder, would also
272 tremendously influence the individual's decision on taking or declining the testing. Therefore,
273 population-specific data, both biomedical (carrier rate, copy number of *SMN2*, type of SMA,
274 availability of specific treatment) and sociocultural aspect (religion and extended socio-
275 educational supports) are highly essential for policy planning for each country.

276 SMA fits all the criteria for prenatal carrier screening, as follows: 1) severity of the
277 disorder; 2) high carrier frequency in the general population more than 1 in 100; 3) available
278 carrier screening test with a high sensitivity and specificity; 4) availability of prenatal diagnosis
279 during early gestation; and 5) timely turnaround time for the screening test and fetal diagnosis
280 [22, 28].

281 The impact of population-based carrier screening for SMA has been well shown in Israel
282 by that 31% of the cases were prenatally diagnosed following the introduction of the screening
283 through healthcare service and insurance plans (since 2008), and even higher at 52% after it
284 became the national program (since 2013) [30].

285 To date, Thailand has had a successful prenatal carrier screening program for thalassemia
286 using a sequential testing strategy. Both thalassemia and SMA are inherited in an autosomal
287 recessive fashion. We believe that it is highly pragmatic to incorporate the SMA screening along
288 with thalassemia screening program for Thai population. However, public education of SMA and
289 additional training for healthcare professionals especially those in family medicine and prenatal
290 setting are required. Moreover, the SMA carrier screening can be further expanded to the pre-
291 conceptional period.

292 To our knowledge, this study is the first study to evaluate the acceptance of prenatal
293 SMA carrier screening and its influencing factors among Thai population, using a prepared set of
294 educational materials and counseling program. The study is one of a very few studies of its kind,
295 among Asian populations and low-middle income countries which is underrepresented in the
296 literature. The validated Thai-language brochure and the whole process of testing strategy which
297 were approved for its usefulness by the participants could be applied to a large-scale screening
298 among Thai population. Lastly, this is the first demonstration of copy number of *SMN2* among
299 general population of Thais.

300 The authors appreciated limitations of the study, including a small sample size, the
301 absence of couples at risk and affected fetus identified, which might have resulted in different
302 answers on choosing fetal diagnosis and pregnancy outcome.

303 **Conclusion**

304 The acceptance rate for prenatal SMA carrier screening was high among Thai pregnant
305 women and it could be further amplified by effective mass education to general population and
306 affordable screening services. The estimated prevalence and carrier frequency of SMA among
307 Thai population was found equivalent to the worldwide data and the majority of patients were
308 predicted to have the most severe type of SMA, necessitating the needs for national program for
309 disease prevention. Population-specific data, both biomedical and sociocultural aspects, are
310 markedly important for national policy planning for the carrier screening.

311 **Acknowledgements**

312 We are thankful of the Faculty of Medicine Ramathibodi Hospital, Mahidol University for
313 providing Research Career Development Awards to DW, TT, and DD. We thank Melissa
314 Leffler, MBA, from Edanz (www.edanz.com/ac) for editing a draft of this manuscript.

315 **Authors' contributions**

316 Conceptualization: Chayada Tangshewinsirikul, Takol Chareonsirisuthigul, Donniphat
317 Dejsuphong, Duangrurdee Wattanasirichaigoon

318 Data curation: Chayada Tangshewinsirikul, Maneerat Prakobpanich, Takol Chareonsirisuthigul

319 Formal analysis: Chayada Tangshewinsirikul, Takol Chareonsirisuthigul, Duangrurdee
320 Wattanasirichaigoon

321 Funding Acquisition: Chayada Tangshewinsirikul

322 Investigation: Chayada Tangshewinsirikul, Panyu Panburana, Maneerat Prakobpanich, Takol
323 Chareonsirisuthigul, Donniphat Dejsuphong, Thipwimol Tim-aroon, Duangrurdee
324 Wattanasirichaigoon

325 Methodology: Chayada Tangshewinsirikul, Panyu Panburana, Maneerat Prakobpanich, Takol
326 Chareonsirisuthigul, Donniphat Dejsuphong, Thipwimol Tim-aroon, Chaiyos Khongkhatithum,
327 Thanyachai Sura, Atchara Tunteeratum, Duangrurdee Wattanasirichaigoon

328 Supervision: Duangrurdee Wattanasirichaigoon

329 Writing– original draft: Chayada Tangshewinsirikul, Takol Chareonsirisuthigul

330 Writing– review & editing: Duangrurdee Wattanasirichaigoon

331 **Data availability statement**

332 The datasets generated and/or analyzed during the current study are not publicly available due to
333 limitations of ethical approval involving the patient data and anonymity but are available from
334 the corresponding author on reasonable request.

335 **Funding**

336 This research was supported by grants from Faculty of Medicine Ramathibodi Hospital, Mahidol
337 University, Bangkok, Thailand (Grant ID RF_64035). The funders had no role in the study
338 design, data collection and analysis, decision to publish, or preparation of the manuscript.

339 **Competing interests**

340 The authors declare that they have no competing interests.

341 **Figure legends**

342 **Figure 1** Sequential prenatal spinal muscular atrophy (SMA) carrier screening protocol

343 **Figure 2** Prenatal carrier screening among 198 pregnant women

344 **Reference**

- 345 1. Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood
346 spinal muscular atrophy. *J Med Genet.* 1978;15(6):409-13.
- 347 2. Prior TW, Leach ME, Finanger E. Spinal Muscular Atrophy. 2000 Feb 24 [Updated
348 2020 Dec 3]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. *GeneReviews*®
349 [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available
350 from: <https://www.ncbi.nlm.nih.gov/books/NBK1352/>


- 351 3. Rashnonejad A, Onay H, Atik T, Atan Sahin O, Gokben S, Tekgul H, et al. Molecular
352 Genetic Analysis of Survival Motor Neuron Gene in 460 Turkish Cases with
353 Suspicious Spinal Muscular Atrophy Disease. *Iran J Child Neurol.* 2016;10(4):30-5.
- 354 4. Verhaart IEC, Robertson A, Leary R, McMacken G, König K, Kirschner J, et al. A
355 multi-source approach to determine SMA incidence and research ready population. *J*
356 *Neurol.* 2017;264(7):1465-73.
- 357 5. Ogino S, Wilson RB, Gold B. New insights on the evolution of the SMN1 and SMN2
358 region: simulation and meta-analysis for allele and haplotype frequency calculations.
359 *Eur J Hum Genet.* 2004;12(12):1015-23.
- 360 6. Coratti G, Ricci M, Capasso A, D'Amico A, Sansone V, Bruno C, et al. Prevalence of
361 Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian
362 Nationwide Survey. *Neurology.* 2023;100(11):522-8.
- 363 7. Lally C, Jones C, Farwell W, Reyna SP, Cook SF, Flanders WD. Indirect estimation
364 of the prevalence of spinal muscular atrophy Type I, II, and III in the United States.
365 *Orphanet J Rare Dis.* 2017;12(1):175.
- 366 8. Arikan Y, Berker Karauzum S, Uysal H, Mihci E, Nur B, Duman O, et al. Evaluation
367 of exonic copy numbers of SMN1 and SMN2 genes in SMA. *Gene.*
368 2022;823:146322.
- 369 9. Aksaralimitsunti M, Sanmaneechai O. Health-related quality of life in Thai children
370 with spinal muscular atrophy. *Pediatr Neonatol.* 2022;63(3):291-7.
- 371 10. Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, Wirth B, et al. Molecular
372 analysis of spinal muscular atrophy and modification of the phenotype by SMN2.
373 *Genet Med.* 2002;4(1):20-6.

- 374 11. Zhao S, Wang W, Wang Y, Han R, Fan C, Ni P, et al. NGS-based spinal muscular
375 atrophy carrier screening of 10,585 diverse couples in China: a pan-ethnic study. *Eur*
376 *J Hum Genet.* 2021;29(1):194-204.
- 377 12. Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy
378 (SMA). *Hum Genet.* 2002;111(6):477-500.
- 379 13. Sun Y, Ma S, Xiao J, Wu J, Wu Y, Shi X, et al. Preconception or prenatal acceptance
380 of SMN1 gene carrier screening and carrier rate of spinal muscular atrophy: a
381 retrospective study in 18,818 reproductive age women in Wuhan area of China. *J*
382 *Assist Reprod Genet.* 2024;41(1):127-33.
- 383 14. Tan J, Zhang J, Sun R, Jiang Z, Wang Y, Ma D, et al. Evaluating the performance of
384 four assays for carrier screening of spinal muscular atrophy. *Clin Chim Acta.*
385 2023;548:117496.
- 386 15. Huang Z, Yang Q, Ye J, Huang J, Lin J, Chen J, et al. Screening and prenatal
387 diagnosis of survival motor neuron gene deletion in pregnant women in Zhaoqing
388 city, Guangdong Province. *BMC Med Genomics.* 2023;16(1):39.
- 389 16. Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfes EM, et al. Pan-ethnic
390 carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical
391 laboratory analysis of >72,400 specimens. *Eur J Hum Genet.* 2012;20(1):27-32.
- 392 17. Wood SL, Brewer F, Ellison R, Biggio JR, Edwards RK. Prenatal Carrier Screening
393 for Spinal Muscular Atrophy. *Am J Perinatol.* 2016;33(12):1211-7.
- 394 18. Feldkötter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of
395 SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier

- 396 testing and prediction of severity of spinal muscular atrophy. *Am J Hum Genet.*
397 2002;70(2):358-68.
- 398 19. Cusin V, Clermont O, Gérard B, Chantereau D, Elion J. Prevalence of SMN1 deletion
399 and duplication in carrier and normal populations: implication for genetic
400 counselling. *J Med Genet.* 2003;40(4):e39.
- 401 20. Hendrickson BC, Donohoe C, Akmaev VR, Sugarman EA, Labrousse P,
402 Boguslavskiy L, et al. Differences in SMN1 allele frequencies among ethnic groups
403 within North America. *J Med Genet.* 2009;46(9):641-4.
- 404 21. Smith M, Calabro V, Chong B, Gardiner N, Cowie S, du Sart D. Population screening
405 and cascade testing for carriers of SMA. *Eur J Hum Genet.* 2007;15(7):759-66.
- 406 22. Prior TW. Carrier screening for spinal muscular atrophy. *Genet Med.*
407 2008;10(11):840-2.
- 408 23. Committee Opinion No. 691: Carrier Screening for Genetic Conditions. *Obstet*
409 *Gynecol.* 2017;129(3):e41-e55.
- 410 24. Wanapirak C, Tongsong T, Sirivatanapa P, Sa-nguansermisri T, Sekararithi R,
411 Tuggapichitti A. Prenatal strategies for reducing severe thalassemia in pregnancy. *Int*
412 *J Gynaecol Obstet.* 1998;60(3):239-44.
- 413 25. Paiboonsukwong K, Jopang Y, Winichagoon P, Fucharoen S. Thalassemia in
414 Thailand. *Hemoglobin.* 2022;46(1):53-7.
- 415 26. Dejsuphong D, Taweewongsounton A, Khemthong P, Chitphuk S, Stitchantrakul W,
416 Sritara P, et al. Carrier frequency of spinal muscular atrophy in Thailand. *Neurol Sci.*
417 2019;40(8):1729-32.

- 418 27. Chaisomchit S, Thongnoppakhun W, Pho-iam T, Limwongse C, Likasitwattanakul S,
419 Chareonsiriwatana W, et al. Investigation of carrier frequency for spinal muscular
420 atrophy in Thailand using dried blood spot specimens. *Genomics and Genetics*.
421 2016;9(2&3): 78-84.
- 422 28. Prior TW, Snyder PJ, Rink BD, Pearl DK, Pyatt RE, Mihal DC, et al. Newborn and
423 carrier screening for spinal muscular atrophy. *Am J Med Genet A*.
424 2010;152a(7):1608-16.
- 425 29. Li Y, Wang L, Tan J, Huang M, Wang Y, Shao B, et al. Current attitudes toward
426 carrier screening for spinal muscular atrophy among pregnant women in Eastern
427 China. *J Genet Couns*. 2023;32(4):823-32.
- 428 30. Aharoni S, Nevo Y, Orenstein N, Basel-Salmon L, Ben-Shachar S, Mussaffi H, et al.
429 Impact of a national population-based carrier-screening program on spinal muscular
430 atrophy births. *Neuromuscul Disord*. 2020;30(12):970-4.
- 431 31. Boardman FK, Young PJ, Warren O, Griffiths FE. The role of experiential knowledge
432 within attitudes towards genetic carrier screening: A comparison of people with and
433 without experience of spinal muscular atrophy. *Health Expect*. 2018;21(1):201-11.
434
435

Sequential prenatal SMA carrier screening protocol



Figure




Figure 2 Prenatal carrier screening among 198 pregnant women